Tagraxofusp-erzs

{{DrugProjectFormSinglePage |authorTag= Uma Maveli[1]

|genericName=generic name |aOrAn=a |drugClass= antineoplastic biologic response modulator |indicationType= treatment |indication= |hasBlackBoxWarning=Yes |adverseReactions=Some adverse reactions that occur in patients undergoing treatment with Tagraxofusp-erzs are capillary leak syndrome, nausea, fatigue, peripheral edema, pyrexia, and weight gain. Some lab abnormalities that occur include decreases in albumin, platelets, hemoglobin, calcium, sodium, and increases in glucose,ALT, and AST.

|blackBoxWarningTitle= WARNING: CAPILLARY LEAK SYNDROME |blackBoxWarningBody=

• There have been fatal and life-threatening cases of Capillary Leak Syndrome
• Before initiating treatment, check patient to ensure proper cardiac function and that serum albumin is greater than 3.2 g/dL
• Measure Albumin levels periodically during treatment, and monitor closely after ending treatment for a period of time that is clinically instructed
• Additionally, assess patients periodically and monitor carefully for signs or symptoms of CLS. Some signs and symptoms include weight gain, edema (new or progressively deteriorating), pulmonary edema, hypotension, orhemodynamic instability

|fdaLIADAdult=

ELZONRIS is indicated for:

• ELZONRIS is indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm
• It is a CD123-directed cytotoxin for the treatment of the specific cancer
• This medication is administered to adult patients and pediatric patients 2 years and older with this type of cancer

Dosing Considerations

• Before initiating treatment of ELZONRIS, guarantee that the serum albumin is greater than or equal to 3.2 g/dL
• Patients with H1- histamine antagonist, H2- histamine antagonist, corticosteroids, and acetaminophen should be premedicated about 1 hour before initiating the ELZONRIS dose
• The patients should be monitored after the first cycle of administration in an in person setting for up to 24 hours after initiation of the last infusion
• The following cycles should be administered in an inpatient setting as well, or in a setting containing the equipment needed to treat and monitor the patients hematopoietic malignancies. Patients should be monitored for 4 hours following the previous infusion.